Newegg Commerce Inc vs uniQure N.V. Ordinary Shares — how do they compare? Newegg Commerce Inc trades at $10.79 (market cap $232.74M), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 6.4× Newegg Commerce Inc's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Newegg Commerce Inc for 14 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NEGG | QURE | |
|---|---|---|
Market Cap | $232.74M | $1.48B |
Volume | 40,856 | 2,488,780 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $70.59 |
52-Week Low | $10.61 | $9.03 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $202.98M | $728.62M |
Signals from Pluang's Aura AI — not financial advice
NEGG trades at $10.61, down 6.52% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported revenue of $1.44 billion in 2025 with a net loss of $4.88 million, though recent quarters have beaten EPS estimates. Valuation ratios show a low P/S of 0.17 but a P/E of 24.52, while cash flow trends indicate reliance on financing activities. Recent news highlights partnerships with Western Digital and Hewlett Packard Enterprise to support IT infrastructure.
The outlook is mixed: improving profitability and strategic partnerships offer upside, but persistent net losses, negative operating cash flow, and insider selling pose risks. Analyst consensus is Buy with a $7.75 price target, below the current price, suggesting cautious optimism amid operational challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →